CTI BioPharma Corp.

CTI reported $21.1 million in net revenue for Q4 2022 and $53.9 million in net sales for the first nine months of commercialization, all from VONJO. Management said Q4 sales increased 16% sequentially and that product sales reduced operating loss while SG&A investment continued. Cash, cash equivalents and short-term investments were $79.9 million at December 31, 2022, and the company received $6.5 million more from its royalty agreement in January 2023. Forward-looking, CTI said it expects to be cash flow positive by the end of 2023, but it did not provide formal guidance because gross-to-net is still variable.

Adam Craig framed 2022 as a transition year, saying CTI moved from an R&D company to a fully integrated biopharma with a commercial franchise. He emphasized VONJO’s launch progress, the ASH data on pacritinib’s ACVR1 inhibition and anemia biology, and said the company is pursuing longer-term value through additional indications. His tone was upbeat but disciplined, repeatedly stressing quarter-over-quarter revenue growth, scientific education, and careful commercialization.

David Kirske focused on the reported numbers and balance sheet, citing $21.1 million in Q4 net revenue, $53.9 million in net sales for the first nine months of commercialization, and $79.9 million in cash and investments at year-end. He said holiday seasonality is normal for oncology drugs and that product sales helped reduce operating loss even as SG&A spending rose for commercialization. He also noted the $6.5 million royalty funding received in January and said the company’s objective is cash flow positivity by end-2023, though any major changes to development plans or other transactions could alter that outlook.

Analysts pressed on the Q4 seasonality, the mix of on-label versus off-label use, the size and future of the DRI milestone, and whether the company would give more guidance. Management said seasonality was driven by holidays and the ASH meeting, declined to disclose the milestone threshold, and said the payment is already included in cash forecasts. On the clinical side, Adam Craig said the anemia findings from ASH are post-hoc and unlikely to enter the label, though mechanistic ACVR1 data could potentially be used; he also said the PACIFICA trial will assess anemia benefit and that the company is increasing MSL resources rather than launching a larger study now.